FATE THERAPEUTICS INC Revenue Breakdown
No Revenue Breakdown for FATE on this site yet.
- 2025-12-31: Others Not split by product in the filing$6.65M100.00%; Total revenue $6.65M.
- 2024-12-31: Others Not split by product in the filing$13.63M100.00%; Total revenue $13.63M.
- 2023-12-31: Others Not split by product in the filing$63.53M100.00%; Total revenue $63.53M.
- 2022-12-31: Others Not split by product in the filing$96.30M100.00%; Total revenue $96.30M.
Source checked: the stored Revenue Breakdown page for FATE.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $6.65M 100.00% | $6.65M |
| 2024-12-31 | Not split by product in the filing $13.63M 100.00% | $13.63M |
| 2023-12-31 | Not split by product in the filing $63.53M 100.00% | $63.53M |
| 2022-12-31 | Not split by product in the filing $96.30M 100.00% | $96.30M |
| 2021-12-31 | Not split by product in the filing $55.85M 100.00% | $55.85M |
| 2020-12-31 | Not split by product in the filing $31.43M 100.00% | $31.43M |
| 2019-12-31 | Not split by product in the filing $10.68M 100.00% | $10.68M |
| 2018-12-31 | Not split by product in the filing $4.74M 100.00% | $4.74M |
| 2017-12-31 | Not split by product in the filing $4.11M 100.00% | $4.11M |
| 2016-12-31 | Not split by product in the filing $4.40M 100.00% | $4.40M |
| 2015-12-31 | Not split by product in the filing $2.43M 100.00% | $2.43M |
| 2013-12-31 | Not split by product in the filing $971.00K 100.00% | $971.00K |
| 2012-12-31 | Not split by product in the filing $2.67M 100.00% | $2.67M |
| 2011-12-31 | Not split by product in the filing $1.17M 100.00% | $1.17M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $2.08M 100.00% | $2.08M |
| 2026-03-31 | Not split by product $1.30M 100.00% | $1.30M |
| 2025-12-31 | Not split by product $1.37M 100.00% | $1.37M |
| 2025-09-30 | Not split by product $1.74M 100.00% | $1.74M |
| 2025-06-30 | Not split by product $1.91M 100.00% | $1.91M |
| 2025-03-31 | Not split by product $1.63M 100.00% | $1.63M |
| 2024-12-31 | Not split by product $1.86M 100.00% | $1.86M |
| 2024-09-30 | Not split by product $3.07M 100.00% | $3.07M |
| 2024-06-30 | Not split by product $6.77M 100.00% | $6.77M |
| 2024-03-31 | Not split by product $1.93M 100.00% | $1.93M |
| 2023-12-31 | Not split by product $1.68M 100.00% | $1.68M |
| 2023-09-30 | Not split by product $1.94M 100.00% | $1.94M |
| 2023-06-30 | Not split by product $933.00K 100.00% | $933.00K |
| 2023-03-31 | Not split by product $58.98M 100.00% | $58.98M |
| 2022-12-31 | Not split by product $44.36M 100.00% | $44.36M |
| 2022-09-30 | Not split by product $14.98M 100.00% | $14.98M |
| 2022-06-30 | Not split by product $18.55M 100.00% | $18.55M |
| 2022-03-31 | Not split by product $18.41M 100.00% | $18.41M |
| 2021-12-31 | Not split by product $17.07M 100.00% | $17.07M |
| 2021-09-30 | Not split by product $14.22M 100.00% | $14.22M |
| 2021-06-30 | Not split by product $13.41M 100.00% | $13.41M |
| 2021-03-31 | Not split by product $11.14M 100.00% | $11.14M |
| 2020-12-31 | Not split by product $15.90M 100.00% | $15.90M |
| 2020-09-30 | Not split by product $7.56M 100.00% | $7.56M |
| 2020-06-30 | Not split by product $5.46M 100.00% | $5.46M |
| 2020-03-31 | Not split by product $2.52M 100.00% | $2.52M |
| 2019-12-31 | Not split by product $2.80M 100.00% | $2.80M |
| 2019-09-30 | Not split by product $2.43M 100.00% | $2.43M |
| 2019-06-30 | Not split by product $2.82M 100.00% | $2.82M |
| 2019-03-31 | Not split by product $2.63M 100.00% | $2.63M |
| 2018-12-31 | Not split by product $1.66M 100.00% | $1.66M |
| 2018-09-30 | Not split by product $1.03M 100.00% | $1.03M |
| 2018-06-30 | Not split by product $1.03M 100.00% | $1.03M |
| 2018-03-31 | Not split by product $1.03M 100.00% | $1.03M |
| 2017-12-31 | Not split by product $1.03M 100.00% | $1.03M |
| 2017-09-30 | Not split by product $1.03M 100.00% | $1.03M |
| 2017-06-30 | Not split by product $1.03M 100.00% | $1.03M |
| 2017-03-31 | Not split by product $1.03M 100.00% | $1.03M |
| 2016-12-31 | Not split by product $1.03M 100.00% | $1.03M |
| 2016-09-30 | Not split by product $1.03M 100.00% | $1.03M |
| 2016-06-30 | Not split by product $1.03M 100.00% | $1.03M |
| 2016-03-31 | Not split by product $1.32M 100.00% | $1.32M |
| 2015-12-31 | Not split by product $1.08M 100.00% | $1.08M |
| 2015-09-30 | Not split by product $1.03M 100.00% | $1.03M |
| 2015-06-30 | Not split by product $329.00K 100.00% | $329.00K |
| 2013-12-31 | Not split by product $0.00 | $0.00 |
| 2013-09-30 | Not split by product $209.00K 100.00% | $209.00K |
| 2013-06-30 | Not split by product $290.00K 100.00% | $290.00K |
| 2013-03-31 | Not split by product $472.00K 100.00% | $472.00K |
| 2012-12-31 | Not split by product $643.00K 100.00% | $643.00K |
| 2012-09-30 | Not split by product $528.00K 100.00% | $528.00K |
| 2012-06-30 | Not split by product $1.08M 100.00% | $1.08M |
| 2012-03-31 | Not split by product $418.00K 100.00% | $418.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |